Clinical use of liposomal and lipid-complexed amphotericin B.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  1994-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JAC/33.5.907PMID 8089064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS

  1993cited by this paper
• Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.

  1993cited by this paper
• Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

  1992cited by this paper
• Liposomal and Lipid Formulations of Amphotericin B

  1992cited by this paper
• Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.

  1992cited by this paper
• Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs

  1992cited by this paper
• Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

  1992cited by this paper
• Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis

  1992cited by this paper
• Amphotericin B lipid complex therapy of experimental fungal infections in mice

  1991cited by this paper
• Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans

  1991cited by this paper
• Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).

  1991cited by this paper
• Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats

  1991cited by this paper
• Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients.

  1991cited by this paper
• Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

  1991cited by this paper
• Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers

  1991cited by this paper
• Cardiopulmonary toxicity after liposomal amphotericin B infusion.

  1991cited by this paper
• Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis

  1991cited by this paper
• Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

  1991cited by this paper
• Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

  1991cited by this paper
• Amphotericin B: 30 years of clinical experience.

  1990cited by this paper
• In-vitro evaluation of the antifungal activity of amphotericin B entrapped into liposomes during storage for one year.

  1990cited by this paper
• Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

  1990cited by this paper
• Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

  1989cited by this paper
• Successful treatment with liposomal amphotericin B in two patients with persisting fungemia

  1989cited by this paper
• Treatment of systemic fungal infections with liposomal amphotericin B.

  1989cited by this paper
• Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.

  1988cited by this paper
• Hepatic candidiasis in cancer patients: the evolving picture of the syndrome.

  1988cited by this paper
• Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

  1987cited by this paper
• Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

  1987cited by this paper
• Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

  1985cited by this paper
• In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B

  1984cited by this paper
• Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

  1983cited by this paper
• Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

  1981cited by this paper

• Evaluation of lupeol-chitosan nanoparticles infused cellulose acetate membranes for enhanced in-vitro anticancer and antidiabetic activities.

  2024cites this paper
• A Complete Review on : Liposomes

  2024cites this paper
• A Review on Liposomes : A Promising Technique for Drug Delivery System

  2023cites this paper
• A comprehensive review on liposomes: A vesicular system for drug delivery

  2022cites this paper
• Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications

  2022cites this paper
• updated review on topical liposomal gel

  2022cites this paper
• Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route

  2021cites this paper
• Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections

  2021cites this paper
• Recent advances in the development of nanomedicines for the treatment of ischemic stroke

  2021cites this paper
• Development of optimized formulation of liposome using 3-factor Box-Behnken Design

  2021cites this paper
• The Properties of Ion Channels Formed in Bilayer Lipid Membranes by Amphotericin and N-Methyl Derivative of Amphotericin under Their Action on One Side

  2021cites this paper
• Formulation development of Temozolomide liposomal formulation in the treatment of Glioma

  2021cites this paper
• Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy

  2021cites this paper
• Liposomes a Camouflaged Carrier: For Controlled Drug Delivery

  2021cites this paper
• Lipopharmaceuticals- A Critical Review Focused on Recent Advances in Liposomal Drug Delivery

  2020cites this paper
• Targeted nanoparticles for treating infectious diseases

  2019cites this paper
• Dual modality ultrasound - photoacoustic clinical imaging system and its applications

  2018cites this paper
• Polycaprolactone/chitosan blend nanofibers loaded by 5-fluorouracil: An approach to anticancer drug delivery system

  2018cites this paper
• Liposomal Form of the Echinochrome-Carrageenan Complex

  2018cites this paper
• Near-infrared light-responsive liposomal contrast agent for photoacoustic imaging and drug release applications

  2016cites this paper
• Nanocarriers in cosmetology

  2016cites this paper
• Liposomal Amphotericin B Usefulness in Critical Care Unit: A Review Study

  2016cites this paper
• Nanopharmaceuticals (part 1): products on the market

  2014cites this paper
• Multi Lamellar Vesicles (Mlvs) Liposomes Preparation byThin Film Hydration Technique

  2014cites this paper
• NANOCOCHLEATES: A NOVEL APPROACH FOR DRUG DELIVERY

  2014cites this paper
• Liposomes on drug delivery system

  2014cites this paper
• Nanopharmaceuticals ( part 1 ) : products on the market volkmar weissig

  2014cites this paper
• A COMPLETE REVIEW ON : LIPOSOMES

  2012cites this paper
• Nanoparticles as drug carriers

  2012cites this paper
• Multidrug Delivery Systems with Single Formulation——Current status and Future Perspective

  2012cites this paper
• Histological and ultrastructural studies on the effect of Costus Plant and Amphotericin B on male lung rats infected by Aspergillus niger

  2012cites this paper
• Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?

  2012cites this paper
• Liposomes

  2012cites this paper
• Formulation and Evaluation of Long Circulating Liposomal Amphotericin B: A Scinti-kinetic Study using 99mTc in BALB/C Mice

  2011cites this paper
• Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis.

  2010cites this paper
• Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers

  2010cites this paper
• A comparative in vitro study on antifungal and antioxidant activities of Nervilia aragoana and Atlantia monophylla

  2010cites this paper
• Development of Time-Programmed, Dual-Release System Using Multilayered Fiber Mesh Sheet by Sequential Electrospinning

  2010cites this paper
• Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes.

  2010cites this paper
• Antifungal treatment of small animal veterinary patients.

  2010cites this paper
• Antifungal Agents and Antifungal Susceptibility Testing

  2010cites this paper
• Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B

  2009cites this paper
• Antimykotische Prophylaxe bei neutropenischen und immunsupprimierten Patienten

  2009cites this paper
• Amphotericin B incorporated in liquid crystals for lung fungal infection treatment

  2009cites this paper
• Functionalized nanocarrier(s) to image and target fungi infected immune cells.

  2009cites this paper
• CHAPTER 7 – Antifungal therapy

  2009cites this paper
• Preparation, relative toxicity, chemotherapeutic activity, and pharmacokinetics of liposomal SJA-95: a new polyene macrolide antibiotic.

  2008cites this paper
• Amphotericin B formulations and drug targeting.

  2008cites this paper
• Preparation, Relative Toxicity, Chemotherapeutic Activity, and Pharmacokinetics of Liposomal SJA-95: A New Polyene Macrolide Antibiotic

  2008cites this paper
• Coccidioidomycosis In A Cancer Hospital

  2008cites this paper
• A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin

  2006cites this paper
• Optimizing efficacy of amphotericin B through nanomodification

  2006influential citation
• Economic aspects of treatment for fungal infections in cancer patients

  2005cites this paper
• Management of systemic fungal infections: alternatives to itraconazole.

  2005cites this paper
• Nephrology Dialysis Transplantation Nosocomial outbreak of A spergillus fumigatus infection among patients in a renal unit ?

  2005cites this paper
• Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.

  2005cites this paper
• Coccidioidomycosis in Renal Transplant Recipients

  2005cites this paper
• Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages.

  2005cites this paper
• Lipid-based formulations of amphotericin B.

  2004cites this paper
• A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

  2004cites this paper
• Update on antifungal therapy.

  2003cites this paper
• Antifungal drug therapy in avian species.

  2003cites this paper
• Recommendations for the treatment of fungal pneumonias

  2003cites this paper
• Antifungal therapy--state of the art at the beginning of the 21st century.

  2003cites this paper
• The lipid formulations of amphotericin B

  2003cites this paper
• Amphotericin B: time for a new "gold standard".

  2003cites this paper
• Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P

  2002cites this paper
• Molecular modeling of amphotericin B-ergosterol primary complex in water II.

  2002cites this paper
• Molecular modelling of amphotericin B-ergosterol primary complex in water.

  2002cites this paper
• Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B

  2002cites this paper
• Candida Infections in the Intensive Care Unit

  2002cites this paper
• Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients.

  2001cites this paper
• Cryotherapy in the Diagnosis of Endobronchial Mucormycosis

  2001cites this paper
• PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED β-CYCLODEXTRINS

  2001cites this paper
• Should we target signal pathways instead of single mediators in the treatment of sepsis?

  2001cites this paper
• Aspergillosis in bone marrow transplant recipients.

  2000cites this paper
• Systemic antifungal drugs.

  2000cites this paper
• Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole

  2000cites this paper
• Biodistribution of Amphotericin B When Delivered Through Cholesterol Hemisuccinate Vesicles in Normal and A. Fumigatus Infected Mice

  2000cites this paper
• New developments in the diagnosis and management of invasive fungal infections.

  2000cites this paper
• [Antibiotics and kidney]

  2000cites this paper
• Antifungal compounds: controversies, queries and conclusions.

  2000cites this paper
• Targeted prophylaxis with amphotericin B lipid complex in liver transplantation

  2000cites this paper
• Lipid-based formulations of amphotericin B.

  2000cites this paper
• Ligand directed macrophage targeting of amphotericin B loaded liposomes.

  2000cites this paper
• Evaluation of the in‐line filters for the intravenous infusion of amphotericin B fluid

  1999cites this paper
• Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani

  1999cites this paper
• Successful lipid-complexed amphotericin B treatment of Candida arthritis in a lymphoma patient.

  1999cites this paper
• AmBisome: an overview of current use.

  1999cites this paper
• New directions in antimicrobial therapy.

  1999cites this paper
• Current Strategies in the Treatment of Invasive Aspergillus Infections in Immunocompromised Patients

  1999cites this paper
• Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability

  1999cites this paper
• Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: a 2 year review.

  1999cites this paper
• The plasma lipoprotein distribution of amphotericin b lipid complex is influenced by the coat lipid content of high density lipoproteins

  1999cites this paper
• Although amphotericin B has been the gold standard in treating systemic fungal infections, its use is limited by side-effects including nephrotoxicity. In contrast the empiric or therapeutic use of AmBisome is better tolerated, with less nephrotoxicity. AmBisome: of current use

  1999cites this paper
• Antifongiques

  1999cites this paper
• Approach to fever in the neutropenic host.

  1998cites this paper
• In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.

  1998cites this paper
• [Current concepts of liposomes and the outlook for their use in pulmonology].

  1998cites this paper
• Liposomal Amphotericin B

  1998influential citation